<p>The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was completed in 2006. However, participants have been under follow-up for cancer incidence and mortality since that time. In addition, PLCO included a large biological sample biorepository which has served as a unique resource for cancer research, particularly for etiologic and early-marker studies. As part of these efforts, PLCO has been used for a large number of genome-wide association and exome sequencing studies for different types of cancer. Recently, a blood DNA methylation analysis was conducted in annexes case-controls study of breast cancer.</p>

The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)

Neoplasms study with Methylation (CpG), SNP/CNV (Array) + 1 more data on dbGaP (110,559 participants)

The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)

Description

Applying For Access

Summary